Bristol-Myers Squibb has entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the US. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

As part of the I-O RPM program, Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center will conduct a range of early-phase clinical studies and Bristol-Myers Squibb will fund positions within The Johns Hopkins University School of Medicine fellowship program.

The I-O RPM research program is a multi-institutional initiative with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute, Moffitt Cancer Center and now the Johns Hopkins Kimmel Cancer Center. I-O RPM builds on Bristol-Myers Squibb's formation in 2012 of the International Immuno-Oncology Network (II-ON), which is a global collaboration between Bristol-Myers Squibb and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice.

Source: Bristol-Myers Squibb